Results A total of 126 patients (median age age: 63.6 years 64 male individuals) were included in the validation cohort, and the combined cohort (validation and original cohorts combined) had a total of 248 patients (median patient age: 63.3 years 126 male individuals). Main Outcomes and Measures The primary outcome was progression-free survival (PFS) and was estimated by the Kaplan-Meier method a Cox proportional-hazards model adjusting for primary tumor site, tumor grade, and number of PRRT doses administered was used to analyze association between CS and outcomes. Statistical analysis was performed from June to November 2021.Įxposures PRRT with 177Lu-dotatate or alternate therapies such as everolimus, sunitinib, or capecitabine plus temozolomide. Patients with paragangliomas, pheochromocytomas and neuroblastomas were excluded. The validation cohort included patients from Ochsner Medical Center, Markey Cancer Center, and Rush Medical Center. The original cohort included patients from Vanderbilt-Ingram Cancer Center. Objective To assess whether the prognostic ability of the clinical score (CS) could be validated in an external cohort of patients with WD NETs.ĭesign, Setting, and Participants This multicenter cohort study’s analysis included patients with WD NETs who were under consideration for peptide receptor radionuclide therapy (PRRT) with lutetium-177 ( 177Lu)-dotatate between March 1, 2016, and March 17, 2020.
Importance Despite the benefit of peptide receptor radionuclide therapy (PRRT) for patients with well-differentiated neuroendocrine tumors (WD NETs), no clinical metric to anticipate benefit from the therapy for individual patients has been previously defined. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.
0 kommentar(er)
